IShares Biotechnology Price To Earning vs. Five Year Return

IBB Etf  USD 139.91  1.95  1.41%   
Based on the key profitability measurements obtained from IShares Biotechnology's financial statements, iShares Biotechnology ETF may not be well positioned to generate adequate gross income at the present time. It has a very high likelihood of underperforming in December. Profitability indicators assess IShares Biotechnology's ability to earn profits and add value for shareholders.
For IShares Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of IShares Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well iShares Biotechnology ETF utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between IShares Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of iShares Biotechnology ETF over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

iShares Biotechnology ETF Five Year Return vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining IShares Biotechnology's current stock value. Our valuation model uses many indicators to compare IShares Biotechnology value to that of its competitors to determine the firm's financial worth.
iShares Biotechnology ETF is considered the top ETF in price to earning as compared to similar ETFs. It also is considered the top ETF in five year return as compared to similar ETFs reporting about  1.23  of Five Year Return per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IShares Biotechnology's earnings, one of the primary drivers of an investment's value.

IShares Five Year Return vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

IShares Biotechnology

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
3.16 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.

IShares Biotechnology

Five Year Return

 = 

(Mean of Monthly Returns - 1)

X

100%

 = 
3.90 %
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.

IShares Five Year Return Comparison

IShares Biotechnology is currently under evaluation in five year return as compared to similar ETFs.

IShares Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in IShares Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, IShares Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of IShares Biotechnology's change in net profit over the period of time. It can combine multiple indicators of IShares Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Nasdaq Biotechnology is traded on NASDAQ Exchange in the United States.

IShares Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on IShares Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of IShares Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the IShares Biotechnology's important profitability drivers and their relationship over time.

Use IShares Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if IShares Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IShares Biotechnology will appreciate offsetting losses from the drop in the long position's value.

IShares Biotechnology Pair Trading

iShares Biotechnology ETF Pair Trading Analysis

The ability to find closely correlated positions to IShares Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace IShares Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back IShares Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iShares Biotechnology ETF to buy it.
The correlation of IShares Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as IShares Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iShares Biotechnology ETF moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for IShares Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your IShares Biotechnology position

In addition to having IShares Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Thematic Idea Now

Obamacare
Obamacare Theme
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
View All  Next Launch
When determining whether iShares Biotechnology ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Biotechnology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Biotechnology Etf:
Check out Risk vs Return Analysis.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
To fully project IShares Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of iShares Biotechnology ETF at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include IShares Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential IShares Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although IShares Biotechnology investors may work on each financial statement separately, they are all related. The changes in IShares Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on IShares Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.